Novartis’s New Lung Disease Drug Trumps GSK’s Advair in Study
Shares of Swiss pharmaceutical company Novartis were up about 1.5% in morning trading Monday following its announcement over the weekend that its Onbrez Breezhaler was found to be more effective at treating lung disease than a…